My Cart
Overview
mRNA Features
Platform History
Overview - One step from targets to mAb
Sanyou Bio innovative mRNA to mAb service provides one-stop solution from target sequences to monoclonal antibody production in only 12 weeks, also including customized QA services for mRNA and LNP packaging (see the detailed procedures below). Contact with our experts for a customized service plan.
Varlous antigen selection: includes difficult-to-express targets such as multi-pass transmembrane proteins.
Al-drlven codon design: improves mRNA stability and protein expression.
GMP materlal preparation: generates high quality plas- mid with low endotoxin level<10 EU/mg.
In-vitro mRNA transcrlp- tion: includes difficult-to-express targets such as multi-pass transmembrane proteins.
mRNA LNP packaging: guarantees the efficient delivery of mRNA-LNP with quality assurance.
Diverse animal models: includes mouse, rabbit, alpaca and lama.
Automated Ab screening Platform: takes only 3 weeks from library establishment to full-length Ab construction.
mRNA Features
The Sanyou Bio mRNA mAb platform integrates the strengths of mRNA technology with Sanyou's well-established antibody design, discovery, and production systems, overcoming the challenges of antigen production and antibody generation for complex and difficult targets. It is compatible with traditional immunization strategies to offer new solutions to antibody discovery.
mRNA Immunization over others
Cost for raw material preparation
Time for raw material preparation
Complex targets（i.e. GPCR，ICR）
Immunization dose
Immunization period
Adjuvant
Efficacy
Non-specific binding
Storage conditions
Cell boosted
High
Slow
√
High
10 week（biweekly）
Optional
High
High
-20°C，long time
Protein boosted
Mid-low
Mid
√
Mid
10 week（biweekly）
Freunds Adjuvant
Mid
Mid-low
-20°C，long time
VLP boosted
Mid-low
Mid
√
Mid
10 week（biweekly）
Freunds Adjuvant
Mid
Mid-low
-20°C，long time
mRNA boosted
Low
Fast
√
Low
6 week（biweekly）
Optional
Mid-high
Low
-80°C，short time
Advantages of mRNA mAb Technology
Solution for Complex Targets
mRNA-delivered antigens retain natural conformation in vivo.
Addressing challenges in complex target preparation such as multi-pass transmembrane proteins, ion channel proteins etc.
Complement Immunization Strategy
Various animal models available such as rabbit, mouse, alpaca.
mRNA can be combined with traditional immunization ways (protein, cell) to increase immunogenicity.
Speed up Antibody Discovery Cycle
mRNA as a self adjuvant enhances immunogenicity in vivo with no need for additional adjuvant.
Besides being cost-effective, mRNA immunization period takes only 6 weeks with high efficacy, 4 weeks shorter than traditional pathways.
Lower Non-Specificity
Antibody candidates obtained from mRNA immunization have high specificity to target cells with low non-specificity to other cells.
Platform History - Sanyou Bio mRNA mAb Development
Since 2015, Sanyou Bio has pioneered antibody technology innovations, evolving from phage display to magnetic array immunization systems (2016-2023) that enabled its mRNA-mAb platform. Following rapid 2024 development and optimization, the platform launched commercially in June 2025, delivering next-generation antibody discovery solutions worldwide.
Shanghai, China
T3, 559 Zhuyuan Road,
Minhang, Shanghai, 201112
Boston, USA
1 Broadway, 14th floor,
Cambridge, MA 02142
San Diego, USA
4660 La Jolla Village Dr,
San Diego, CA 92122
London, UK
24/25 The Shard, 32 London
Bridge St. London, SE1 9SG
+86 21 3368 1627
mrnamab@sanyoubio.com
mrna-mab.com
Shanghai, China
T3, 559 Zhuyuan Road, Minhang, Shanghai, 201112
Boston, USA
1 Broadway, 14th floor, Cambridge, MA 02142
San Diego, USA
4660 La Jolla Village Dr, San Diego, CA 92122
London, UK
24/25 The Shard, 32 London Bridge St. London, SE1 9SG
Social media
Overview
mRNA Features
Platform History
Overview - One step from targets to mAb
Sanyou Bio innovative mRNA to mAb service provides one-stop solution from target sequences to monoclonal antibody production in only 12 weeks, also including customized QA services for mRNA and LNP packaging (see the detailed procedures below). Contact with our experts for a customized service plan.
① Varlous antigen selection: includes difficult-to-express targets such as multi-pass transmembrane proteins.
② Al-drlven codon design: improves mRNA stability and protein expression.
③ GMP materlal preparation: generates high quality plas- mid with low endotoxin level<10 EU/mg.
④ In-vitro mRNA transcrlp- tion: includes difficult-to-express targets such as multi-pass transmembrane proteins.
⑤ mRNA LNP packaging: guarantees the efficient delivery of mRNA-LNP with quality assurance.
⑥ Diverse animal models: includes mouse, rabbit, alpaca and lama.
⑦ Automated Ab screening Platform: takes only 3 weeks from library establishment to full-length Ab construction.
mRNA Features
The Sanyou Bio mRNA mAb platform integrates the strengths of mRNA technology with Sanyou's well-established antibody design, discovery, and production systems, overcoming the challenges of antigen production and antibody generation for complex and difficult targets. It is compatible with traditional immunization strategies to offer new solutions to antibody discovery.
mRNA Immunization over others
Cost for raw material preparation
Time for raw material preparation
Complex targets（i.e. GPCR，ICR）
Immunization dose
Immunization period
Adjuvant
Efficacy
Non-specific binding
Storage conditions
Cell boosted
High
Slow
√
High
10 week（biweekly）
Optional
High
High
-20°C，long time
Protein boosted
Mid-low
Mid
√
Mid
10 week（biweekly）
Freunds Adjuvant
Mid
Mid-low
-20°C，long time
Cost for raw material preparation
Time for raw material preparation
Complex targets（i.e. GPCR，ICR）
Immunization dose
Immunization period
Adjuvant
Efficacy
Non-specific binding
Storage conditions
VLP boosted
Mid-low
Mid
√
Mid
10 week（biweekly）
Freunds Adjuvant
Mid
Mid-low
-20°C，long time
mRNA boosted
Low
Fast
√
Low
6 week（biweekly）
Optional
Mid-high
Low
-80°C，short time
Advantages of mRNA mAb Technology
Solution for
Complex Targets
mRNA-delivered antigens retain natural conformation in vivo.
Addressing challenges in complex target preparation such as multi-pass transmembrane proteins, ion channel proteins etc.
Complement
Immunization Strategy
Various animal models available such as rabbit, mouse, alpaca.
mRNA can be combined with traditional immunization ways (protein, cell) to increase immunogenicity.
Speed up
Antibody Discovery Cycle
mRNA as a self adjuvant enhances immunogenicity in vivo with no need for additional adjuvant.
Besides being cost-effective, mRNA immunization period takes only 6 weeks with high efficacy, 4 weeks shorter than traditional pathways.
Lower Non-Specificity
Antibody candidates obtained from mRNA immunization have high specificity to target cells with low non-specificity to other cells.
Platform History - Sanyou Bio mRNA mAb Development
Since 2015, Sanyou Bio has pioneered antibody technology innovations, evolving from phage display to magnetic array immunization systems (2016-2023) that enabled its mRNA-mAb platform. Following rapid 2024 development and optimization, the platform launched commercially in June 2025, delivering next-generation antibody discovery solutions worldwide.
Shanghai, China
T3, 559 Zhuyuan Road,
Minhang, Shanghai, 201112
Boston, USA
1 Broadway, 14th floor,
Cambridge, MA 02142
San Diego, USA
4660 La Jolla Village Dr,
San Diego, CA 92122
London, UK
24/25 The Shard, 32 London
Bridge St. London, SE1 9SG
+86 21 3368 1627
mrnamab@sanyoubio.com
mrna-mab.com
Shanghai, China
T3, 559 Zhuyuan Road, Minhang, Shanghai, 201112
Boston, USA
1 Broadway, 14th floor, Cambridge, MA 02142
San Diego, USA
4660 La Jolla Village Dr, San Diego, CA 92122
London, UK
24/25 The Shard, 32 London Bridge St. London, SE1 9SG
Social media
